In clinical trials
Brain & sleep
Davunetide
Evidence
Clinical trials
Class
Neuroprotective peptide derived from ADNP
KEY TAKEAWAY
Davunetide is an eight-amino-acid peptide derived from a protein called activity-dependent neuroprotective protein. It was developed as an experimental drug for neurodegenerative disease. Davunetide is not FDA-approved. A large trial in progressive supranuclear palsy did not meet its main goals, and development for that use was stopped.
Written by the Veylo editorial team · Updated
November 2026
What it is
Neuroprotective peptide derived from ADNP
Being studied for
Studied in progressive supranuclear palsy and cognitive impairment
Key fact
Davunetide is not FDA-approved. A large trial in progressive supranuclear palsy did not meet its main goals, and development for that use was stopped.
Route
Studied as a nasal spray and by injection
Evidence strength
Clinical trials
Davunetide is an eight-amino-acid peptide derived from a protein called activity-dependent neuroprotective protein. It was developed as an experimental drug for neurodegenerative disease.
It is thought to stabilize microtubules, the internal scaffolding of nerve cells that tau protein normally supports.
Davunetide is not FDA-approved. A large trial in progressive supranuclear palsy did not meet its main goals, and development for that use was stopped.
Studied in progressive supranuclear palsy and cognitive impairment.
Trials reported mostly mild side effects, but long-term safety data are limited.
Davunetide: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.